3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Prostatic Neoplasms
19
Glioblastoma
18
Breast Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
15
Lung Neoplasms
12
Rectal Neoplasms
11
Oropharyngeal Neoplasms
10
Neoplasms
9
Head and Neck Neoplasms
8
Glioma
8
Astrocytoma
8
Neoplasm Metastasis
7
Sarcoma
6
Esophageal Neoplasms
6
Carcinoma, Squamous Cell
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Lymphoma, Follicular
5
Hodgkin Disease
5
Gliosarcoma
5
Esophageal Squamous Cell Carcinoma
5
Carcinoma
5
Burkitt Lymphoma
5
Brain Neoplasms
5
Adenocarcinoma of Lung
5
Adenocarcinoma Of Esophagus
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Nasopharyngeal Carcinoma
4
Interventions
Magnetic Resonance Spectroscopy
8
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
lutetium Lu 177 dotatate
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
LY3023414
2
pembrolizumab
1
neratinib
1
cemiplimab
1
brigatinib
1
Watchful Waiting
1
Vincristine
1
Vemurafenib
1
Temozolomide
1
Radiotherapy, Conformal
1
Radiotherapy
1
Radiation
1
Platinum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
Radiotherapy
×
90 days
×
Clear all
NCT04732065
2026-03-17
PNOC023
University of California, San Francisco
Phase 1
Recruiting
208 enrolled